Login to Your Account



Corixa Wants Dispute Resolution For Bexxar Through FDAMA

By Kim Coghill


Thursday, May 16, 2002
Corixa Corp. said it is requesting an appeal of the FDA's complete review letter questioning the net clinical benefit and safety of the company's lead cancer product, known as Bexxar. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription